Trial Profile
A Phase I trial of ASN-500
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2018
Price :
$35
*
At a glance
- Drugs ASN-500 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2018 New trial record
- 28 Jun 2018 According to an Arsanis Biosciences media release, the company plans to initiate this trial in 2019.